Nubeqa already marketedss?

Is Nubeqa (darolutamide) already marketed?

Yes. Nubeqa (darolutamide) has already been marketed, including in the U.S., where it was approved for certain patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for metastatic hormone-sensitive prostate cancer (mHSPC) in later indications.

Where has Nubeqa been approved/available?

Nubeqa’s availability depends on the country, because approvals happen by regulator (FDA in the U.S., EMA in Europe, and other national agencies elsewhere). The key point is that it is not a “pipeline” product; it is an already-approved medicine in major markets.

What Nubeqa is used for once it’s marketed

Because Nubeqa is an oral androgen receptor inhibitor, it’s used for prostate cancer settings defined by hormone sensitivity and metastatic status (as described in its approved indications).

Want the “when” and the exact approval dates?

If you tell me which country (e.g., U.S. FDA vs. EU/EMA) you care about, I can narrow this to the specific approval date(s) and indication(s).

Sources

• DrugPatentWatch.com – Nubeqa (darolutamide) information